Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
15.37
+0.25 (1.65%)
Dec 20, 2024, 4:00 PM EST - Market closed
Dr. Reddy's Laboratories Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for RDY stock has a target of 17, which predicts an increase of 10.61% from the current stock price of 15.37.
Analyst Consensus: Buy
* Price targets were last updated on Nov 6, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for RDY is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $17 → $17 | Buy | Maintains | $17 → $17 | +10.61% | Nov 6, 2024 |
| Barclays | Barclays | Buy Maintains $16 → $17 | Buy | Maintains | $16 → $17 | +13.21% | Jul 30, 2024 |
| Barclays | Barclays | Buy Maintains $16 → $16 | Buy | Maintains | $16 → $16 | +5.40% | May 8, 2024 |
| Barclays | Barclays | Buy Maintains $15 → $16 | Buy | Maintains | $15 → $16 | +4.10% | Jan 29, 2024 |
| Barclays | Barclays | Buy Maintains $13 → $14 | Buy | Maintains | $13 → $14 | -8.91% | Jun 1, 2023 |
Financial Forecast
Revenue This Year
316.55B
from 279.16B
Increased by 13.39%
Revenue Next Year
342.99B
from 316.55B
Increased by 8.35%
EPS This Year
70.07
from 66.80
Increased by 4.89%
EPS Next Year
72.60
from 70.07
Increased by 3.62%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 348.2B | 406.4B | 409.0B | ||
| Avg | 316.5B | 343.0B | 349.6B | ||
| Low | 256.8B | 286.4B | 288.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 24.7% | 28.4% | 19.2% | ||
| Avg | 13.4% | 8.4% | 1.9% | ||
| Low | -8.0% | -9.5% | -16.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 82.43 | 95.72 | 95.42 |
| Avg | 70.07 | 72.60 | 60.02 |
| Low | 41.04 | 50.45 | 43.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 23.4% | 36.6% | 31.4% |
| Avg | 4.9% | 3.6% | -17.3% |
| Low | -38.6% | -28.0% | -40.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.